EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation

Riddhi Doshi, Victoria Divino, Luke Greenwalt, Mitchell DeKoven

Expert Review of Pharmacoeconomics & Outcomes Research · 2025

DOI: 10.1080/14737167.2025.2453503 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Riddhi Doshi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Real World Solutions, IQVIA, Durham, NC, USA. Hauptthemen laut MEDLINE: Comparative Effectiveness Research, Drug Costs, Medicare, Research Design. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The 2022 Inflation Reduction Act is expected to result in lower drug prices for Medicare beneficiaries in the United States (US). The Centers for Medicare & Medicaid Services (CMS) released the most recent draft guidance for the medicare drug price negotiation (DPN) program in May 2024. AREAS COVERED: In August 2023, the list of 10 drugs selected for the DPN were published and the first round of negotiations are now complete. While the latest CMS guidance highlights the importance of considering study limitations, bias, uncertainty, and generalizability, there were scarce methodological guidelines provided for the comparative effectiveness research studies. We conducted searches on PubMed and reviewed resources from websites of regulatory authorities. EXPERT OPINION: Broader domains of data quality, transparency, and methodology including study design, outcomes assessment, bias, confounding and uncertainty should be considered when developing methodological guidelines for evidence submitted for DPN. There is opportunity to align with and leverage existing guidelines published by federal and non-federal organizations in the US and globally while customizing the new guidance based on the specific requirements of DPN, keeping in mind CMS's interest in specific populations as well as health equity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Comparative Effectiveness ResearchDrug CostsMedicareResearch DesignUnited StatesHumansCenters for Medicare and Medicaid Services, U.S.NegotiatingGuidelines as TopicUncertainty

Stichwörter der Autor:innen

Inflation reduction actcenters for medicare & medicaid servicescomparative effectiveness researchdrug price negotiationfood and drug administrationmethodological standards

Autor:innen und Institutionen

  • Real World Solutions, IQVIA, Durham, NC, USA.
  • Market Access Center of Excellence, IQVIA, Boston, MA, USA.

Zitieren

APA

Doshi, R., Divino, V., Greenwalt, L., & DeKoven, M. (2025). Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2453503

Vancouver

Doshi R, Divino V, Greenwalt L, DeKoven M. Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2453503

BibTeX
@article{Doshi2025,
  author = {Doshi, Riddhi and Divino, Victoria and Greenwalt, Luke and DeKoven, Mitchell},
  title = {Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2025},
  doi = {10.1080/14737167.2025.2453503}
}
Kostenlos starten →